$4M Contract Awarded To Develop Drugs Against Infectious Diseases

Kineta's class of molecules have been shown in pre-clinical tests to inhibit diverse viral pathogens including Ebola and respiratory syncytial virus.

The growing market for immunotherapy treatments isn’t just focused on cancer. Seattle biotech Kineta just landed a federal contract from the National Institutes of Health for about $4 million to develop an immunotherapy treatment which would treat a variety of infectious diseases, such as the flu, dengue fever, Ebola and others.

READ FULL ARTICLE Curated publisher From The Business Journals